|
Jul 23
|
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
|
|
Jul 23
|
Nanotechnology in medicine: Who are the leading public companies?
|
|
Jul 17
|
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
|
|
Jun 20
|
Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?
|
|
May 10
|
Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts
|
|
May 10
|
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
|
|
May 8
|
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
|
|
May 8
|
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
|
|
May 8
|
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ...
|
|
May 7
|
Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ...
|
|
May 7
|
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
|
|
May 7
|
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
|
|
Apr 30
|
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
|
|
Apr 11
|
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend
|
|
Apr 4
|
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
|
|
Apr 2
|
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 14
|
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
|
|
Mar 13
|
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
|
|
Mar 9
|
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)
|